9th Annual Biomarkers Congress

View Profile


Speaking/Presenting-Abstract/Poster at Mtg

Topic Authors / presenters Event name Event date
1. Evaluation of the Incremental Value of New Biomarkers 12th Bergmeyer Conference, International Federation of Clinical Chemistry and Laboratory Medicine, Grainau, Garmish-Partenkirchen, Germany March, 2010
2. Predictive Models 9th Uro-Oncology Congress, Turkish Uro-Oncology Society, Ankara, Turkey November, 2009
3. Prediction Models in Medicine: Development, Evaluation and Implementation Society for Medical Decision Making, 31st Annual Meeting, Hollywood, California October, 2009
4. Bladder Cancer Nomograms: What We Have and What We Need ” International Bladder Cancer Network,7th Meeting, Nuernberg, Germany October, 2009
5. Predictive Models – Hot Topics on Bladder Part 1 XIX Congresso Nazionale SIUrO, Milan, Italy June, 2009
6. Predictive Models – Hot Topics on Kidney XIX Congresso Nazionale SIUrO, Milan, Italy June, 2009
7. Comprehensive Risk Calculator for Type 2 Diabetes Using Electronic Medical Records Agency for Healthcare Research and Quality Comparative and Clinical Effectiveness Research Methods: II Symposium, Gaithersburg, Maryland June, 2009
8. Building and Using Nomograms Spanish Association of Urology, Third Educational Course in Urology, Madrid, Spain May, 2009
9. New Approaches to Risk Prediction American Association for Cancer Research, 100th Annual Meeting, Denver Colorado April, 2009
10. Statistical Prediction Models and Medical Decision Making Neue Methoden der Biometrie: 55. Biometrischen Kolloquims 2009, Leibniz University, Hannover, Germany March, 2009
11. Statistical Prediction Department of Biostatistics, University of Copenhagen, Copenhagen, Denmark March, 2009
12. Statistical Prediction Models in Urology Urology Grand Rounds, University of Washington, Seattle, Washington January, 2009
13. Computer Nomograms to Predict the Outcomes of Disease and Interventions Genitourinary Cancer Conference Series, Swedish Medical Center, Seattle, Washington January, 2009
14. Predictive Models Society of Urologic Oncology, 9th Annual Society of Urologic Oncology Meeting, Bethesda, Maryland December, 2008
15. Statistical models for cancer prognosis Cancer/Biostatistics Seminar, Biostatistics Department, University of Michigan, Ann Arbor, Michigan September, 2008
16. Nomograms in prostate cancer – why we still need them. Choosing one The Royal Melbourne Hospital, Department of Urology, Division of Surgery 9th National Prostate Cancer Symposium, Melbourne, Victoria, Australia August, 2008
17. Health related quality of life and prostate cancer Men’s Health Promotion Forum, Prostate Cancer Foundation of Australia (PCFA), Melbourne, Victoria, Australia August, 2008
18. Health related quality of life and prostate cancer The Royal Melbourne Hospital, Department of Urology, Division of Surgery 9th National Prostate Cancer Symposium, Melbourne, Victoria, Australia August, 2008
19. Prognostic Markers: What Improvements in Biomarkers or Imaging Would Lead to Better Prognosis/Risk Stratification? Issues in Clinical Prostate Cancer: Role of Imaging National Cancer Institute, Rockville, Maryland June, 2008
20. Statistical Prediction Models and Medical Decision Making. Dana Farber Cancer Institute, The Lank Center for Genitourinary Oncology, Boston, Massachusetts May, 2008
21. Predictive Models: Where Are We Going? European School of Oncology, Faculty Member, Predictive Modeling in Prostate Cancer, Venice, Italy April, 2008
22. Statistical Prediction Models and Medical Decision Making Mayo Clinic, Department of Health Sciences Research, Rochester, Minnesota March, 2008
23. Statistical Prediction Models and Medical Decision Making Sunnybrooke Odette Cancer Center, Genitourinary Oncology Abbott Visiting Speaker, Toronto, Ontario, Canada January, 2008
24. Putting Theory into Practice – analyzing diabetes care at the Cleveland Clinic using EHR The Center for Business Intelligence (CBI) Forum on Evidence-Based Medicine, Philadelphia, Pennsylvania December, 2007
25. Integration of Multiple Markers and Risk Factors for Diagnosis and Prognosis International Society for Oncodevelopmental Biology and Medicine, 35th Annual Congress, Prague, Czech Republic September, 2007
26. Databases for Outcomes Research American Urological Association Foundation/Society of Basic Urologic Research Annual Summer Research Meeting, Los Angeles, California August, 2007
27. Evaluation of Predictive Accuracy of Genetic Markers Society of Medical Statistics and Clinical Epidemiology, Naples, Italy June, 2007
28. Statistical Prediction Models and Medical Decision Making .” Beth Israel Deaconess Medical Center, Hematology/Oncology Grand Rounds, Boston, Massachusetts May, 2007
29. Prediction Models for Outcomes University California San Francisco, Active Surveillance Conference, San Francisco, California January, 2007
30. Statistical Prediction Models versus Clinical Judgment Northwestern Medical Faculty Foundation, Inc. Grand Rounds Lecture Series, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois November, 2006
31. Treatment Decision Making in Prostate Cancer – The Use of Nomograms The Royal Melbourne Hospital, Department of Urology, Division of Surgery 7th National Prostate Cancer Symposium, Parkville, Victoria, Australia August, 2006
32. Prognostic Factors and the Use of Nomograms for Predicting Outcomes and Making Strategic Decisions in Prostate Cancer Japanese Society of Urologic Oncology 33rd Annual Meeting, Tokyo, Japan July, 2006
33. Disease Modification in MS: Decision Making…A Cancer Model Consortium of Multiple Sclerosis Centers 20th Annual Conference, Scottsdale, Arizona June, 2006
34. Statistical Prediction Models and Medical Decision Making Ohio State – Cleveland Clinic Foundation – Case Western Reserve University Biostatistics Joint Symposium, Columbus, Ohio May, 2006
35. Nomograms in Prostate Cancer. European Association of Urology 21st Annual Congress, Paris, France April, 2006
36. Risk Assessment and Staging of Localized Disease – Clinical Risk and Staging American Society of Clinical Oncology, Prostate Cancer Symposium, San Francisco, California February, 2006
37. Meaningfully Incorporating Nomograms Into Your Clinical Practice Houston Urological Society, Houston, Texas October, 2005
38. Significant and non-Significant Prostate Cancer” and “Decision Making for Prostate Cancer: the Risk of Undertreatment and Overtreatment PSA: Past, Present and Future, Instituto Nazionale Tumori, Milan, Italy September, 2005
39. Creating a Collaborative Staging System for use with SEER Program/Coding System. American Joint Committee on Cancer Annual Meeting, Chicago, Illinois September, 2005
40. Nomograms and Prostate Cancer Prediction 1st International Conference on Urogenital Disorders – from Gene to Clinics, Malmö, Sweden September, 2005
41. Medical Prediction Models Beckman Coulter Science and Technology 2005 Symposium, Fullerton, California August, 2005
42. This House Believes that the Application of Risk Assessment Tools in Clinical Practice is Limited--Against Takeda European Medical Congress in Urology, Barcelona, Spain April, 2005
43. Understanding and Defining Risk 1st Annual New Perspectives on Prostate Cancer Symposium, Roslyn, New York November, 2004
44. Predictive Medicine in Prostate Cancer Management Sistema Congressi, Abano Terme, Italy November, 2004
45. Nomograms and their Integration into the Clinic 1st Annual New Perspectives on Prostate Cancer Symposium, Roslyn, New York November, 2004
46. Risk: Stratification and Risk Assessment Tools Takeda European Medical Congress in Urology, Warsaw Poland October, 2004
47. Cancer Prediction Models Intelligent Data Analysis in Medicine and Pharmacology 2004 Workshop, Palo Alto September, 2004
48. Measuring QOL After Surgery. 4th International Prostate Cancer Congress, Grand Bahama Island, Bahamas July, 2004
49. Comparing the Accuracy of Prediction Models Cancer Risk Prediction Models: A Workshop on Development, Evaluation, and Application, Washington, D. C. May, 2004
50. Risk Stratification and Risk Assessment Tools Leuprorelin European Medical Congress, Lisbon, Portugal April, 2004
51. Use of Nomograms to Predict Individual Cancer Patient Risk The Society of Surgical Oncology Cancer Symposium, New York March, 2004
52. Integrating Risk Into Early Detection Chemoprevention of Prostate Cancer, Reston, Virginia March, 2004
53. Prediction Models at the Bedside Fred Hutchinson Cancer Research Center, Seattle, WA October, 2003
54. Predicting Patient Outcomes with Nomograms. Swedish Hospital, Seattle, WA October, 2003
55. Predictive Value of Nomograms Used in Conjunction with Surgery/Hormonal Therapy Takeda European Medical Congress, Prague, Czech Republic October, 2003
56. The Predictive Value of Nomograms Used in Conjunction with Brachytherapy and Radiotherapy Takeda European Medical Congress, Prague, Czech Republic October, 2003
57. Nomograms for Urologic Malignancies National Medical Association, Annual Meeting, Philadelphia, PA August, 2003
58. Nomograms in Prostate Cancer Third International Prostate Cancer Congress. Southampton, Bermuda July, 2003
59. Predicting Patient Outcomes with Nomograms Urology Grand Rounds, Montefiore Hospital, Bronx, New York June, 2003
60. Predicting Patient Outcomes with Nomograms Indiana University-Purdue University Indianapolis Cancer Center Grand Rounds, Indianapolis, IN May, 2003
61. Predicting Risk with the Use of Nomograms Charles Huggins Symposium. Chicago, IL April, 2003
62. The Predictive Value of Nomograms Used in Conjunction with Brachytherapy and Radiotherapy Takeda European Medical Congress for Urology. Budapest, Hungary March, 2003
63. Risk Assessment in Prostate Cancer NCCN 8th Annual Conference. Hollywood, Florida March, 2003
64. The Predictive Value of Nomograms Used in Conjunction with Surgery/Hormonal Therapy. Takeda European Medical Congress for Urology. Budapest, Hungary March, 2003
65. Modeling Patient Prognosis MD Anderson 10th Annual Genitourinary Oncology Conference, Houston, Texas February, 2003
66. Clinical Prognostic Factors 3rd International Symposium on Genitourinary Cancers, Santa Barbara February, 2003
67. Nomograms for Cancer Prediction MD Anderson, Department of Biostatistics, Houston, Texas February, 2003
68. Should We Predict Health Outcomes The Way We Predict Financial Outcomes? American Statistical Association, New York, New York December, 2002
69. Nomograms as Counseling Tools ciety for Urologic Oncology Annual Meeting, Bethesda, Maryland December, 2002
70. Nomograms and Prediction Models in Prostate and Other Cancers Population Science Conference, Fox Chase Cancer Center, Philadelphia November, 2002
71. Predicting Outcomes: Innovative Use of Neural Networks and Nomograms Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment, Cambridge, Massachusetts November, 2002
72. Prostate Cancer Nomograms ana-Farber Cancer Institute’s Genitourinary Oncology Seminar Series, Boston, Massachusetts October, 2002
73. Predictive Models of Prostate Cancer Progression. Prostate 2002 International Conference, Molecular Mechanisms as Targets in Prostatic Diseases, Liverpool, England September, 2002
74. Algorithms for Prostate Cancer: From Diagnosis to Outcomes 2nd International Prostate Cancer Congress, St. Thomas, U.S.V.I July, 2002
75. Approaches Toward Outcomes Analysis 23rd American Brachytherapy Society Meeting, Orlando Florida May, 2002
76. Predictors of Disease Progression in Prostate Cancer 1st Annual Opinion Leader Summit, Barcelona April, 2002
77. How To Know When You Should Use A Prognostic Model CaPSURE 2002 Investigators Meeting, San Diego, California March, 2002
78. Predicting Clinical Outcome in Prostate Cancer: Nomograms and Other Strategies Department of Urology Grand Rounds, Columbia University, New York January, 2002
79. Prostate Cancer Nomograms: A Tool for Decision Making. MAN to MAN Prostate Cancer Survivors Support Group, American Cancer Society, New York November, 2001
80. Nomograms in the Management of Prostate Cancer Thomas Jefferson University 12th Annual Urology Update Symposium, Philadelphia November, 2001
81. Nomograms for Predicting Outcomes. Informatics Solutions for Prostate Cancer, Toronto October, 2001
82. Cancer Nomograms: A Tool for Decision Making US TOO! Prostate Cancer Survivors Support Group, Memorial Sloan-Kettering Cancer Center, New York October, 2001
83. Decision Making Tables, Which Are Best, And How Accurate Are They? British Columbia Regional International Conference on Prostate Cancer Meeting, Quadra Island, B.C., Canada August, 2001
84. Statistical Models Predicting Relapse After Local Treatments. 1st International Prostate Cancer Conference, San Juan, Puerto Rico June, 2001
85. Can We Predict Outcomes? Issues and Controversies in Prostate Care, Ontario Regional Meeting, Scottsdale, Arizona May, 2001
86. Using Modern Medical Informatics and the Tools of Artificial Intelligence to Develop Risk Profiles MSKCC Course in: Clinical Research and Outcomes Analysis April, 2001
87. Prostate Cancer Nomograms: Devices Which Predict Treatment Outcomes 43rd Science Writers Seminar of the American Cancer Society, Dana Point, California April, 2001
88. Role of Nomograms in Clinically Localized Prostate Cancer Department of Urology, University of Texas M. D. Anderson Cancer Center April, 2001
89. Can We Predict Outcomes? th Annual Issues and Controversies in Prostate Cancer, Chateau Whistler, B.C., Canada March, 2001
90. How to Select Treatment for Prostate Cancer The Princess Margaret Hospital, Toronto, Canada September, 2000
91. The Use Of Nomograms To Reduce Sample Sizes Necessary For Evaluation Of Clinical Markers In Prostate Cancer. 7th Annual CaPCURE Conference, Reno, Nevada September, 2000
92. Outcomes Analysis The Princess Margaret Hospital, Toronto, Canada September, 2000
93. Prostate-Specific Antigen: Screening and Prognosis for Primary and Recurrent Disease 36th American Society of Clinical Oncology Annual Meeting, New Orleans, Louisiana May, 2000
94. Outcomes Research in Prostate Cancer Department of Biostatistics, University of Michigan, Ann Arbor, Michigan April, 2000
95. Treatment Decision Making for Patients with Clinically Localized Prostate Cancer Research Methodology Conference, Department of General Internal Medicine, Cornell University March, 2000
96. Decision Analyses for the Treatment of Clinically Localized Prostate Cancer Department of Urology, University of Hamburg, Germany March, 2000
97. Prognostic Nomograms for Clinically Localized Prostate Cancer Department of Urology, University of Hamburg, Germany March, 2000
98. The Importance of Using a Nomogram when Counseling the Patient with Clinically Localized Prostate Cancer: A Radiation Therapy Example Health Policy Lecture Series, Northwestern University December, 1999
99. Men and Cancer: Emerging Issues. Memorial Sloan-Kettering Cancer Center, CancerSmart Lecture Series November, 1999
100. A Comparison of Techniques to Predict Individual Prognosis – Examples in Prostate Cancer Working Group on Individual Risk Assessment and Breast Cancer. European Institute of Oncology, Milan, Italy October, 1999
101. Are We Closer to Rational Selection? 34th Annual Meeting of the American Society of Clinical Oncology, Los Angeles, California May, 1998
102. Cost Effectiveness of Interferon Therapy in Chronic Myelogenous Leukemia Visiting Faculty: Interferons Update Meeting, Annenberg Center for Health Sciences, Rancho Mirage, California April, 1998
103. The Use of and Misuse of Nomograms for Clinically Localized Prostate Cancer. Radiation Oncology Grand Rounds, Baylor College of Medicine, Houston, Texas February, 1998
104. Recent Developments in Predicting Prognosis with Prostate Cancer US TOO Cancer Support Group, Houston, Texas January, 1997
105. Statistics in the Peer-Review Process American Urological Association Peer-Review Seminar, Dallas, Texas January, 1997
106. Should a SPORE Computer Network be Structured as an Interconnected or Isolated System, with a Web Page or Database Interface, as Read-Only or Interactive? First National Cancer Institute Inter-SPORE Networking Meeting, Bethesda, Maryland January, 1996
107. A Decision Analysis Model for Treating Clinically Localized Prostate Cancer Research Conference, Section of General Internal Medicine, University of Texas, M.D. Anderson Cancer Center, Houston, Texas January, 1995
108. A Model of Machine Learning Technique Performance. Texas Women’s University, Houston, Texas January, 1995
109. A Comparison of Machine Learning Techniques Department of Family Medicine Seminar, Baylor College of Medicine January, 1994
110. Machine Learning Models in Medical Outcomes Research Urology Grand Rounds, Baylor College of Medicine January, 1994
111. The Role of Statistics in the Peer-Review Process American Urological Association Peer Review Seminar, Houston January, 1994



Site wide Speaking/Presenting-Abstract/Poster at Mtg

Presentation Event Month, Year
Nomograms Predicting Recurrence UCSF Radiation Oncology Update: Management of Recurrent Disease May, 2010

4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.